Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis

McClung, 2014, Romosozumab in postmenopausal women with low bone mineral density, N Engl J Med, 370, 412, 10.1056/NEJMoa1305224

Delgado-Calle, 2017, Role and mechanism of action of sclerostin in bone, Bone, 96, 29, 10.1016/j.bone.2016.10.007

Gennari, 2016, Treatment needs and current options for postmenopausal osteoporosis, Expert Opin Pharmacother, 17, 1141, 10.1080/14656566.2016.1176147

Leder, 2015, Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial, Lancet, 386, 1147, 10.1016/S0140-6736(15)61120-5

Cosman, 2013, Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene, J Bone Miner Res, 28, 1328, 10.1002/jbmr.1853

Obermayer-Pietsch, 2008, Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment, J Bone Miner Res, 23, 1591, 10.1359/jbmr.080506

Takada, 2020, Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial, J Bone Miner Metab, 38, 310, 10.1007/s00774-019-01057-1

Kendler, 2019, Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab, Osteoporos Int, 30, 2437, 10.1007/s00198-019-05146-9

Ebina, 2020, Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis, Bone, 140, 115574, 10.1016/j.bone.2020.115574

Kashii, 2020, Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report, Bone Rep, 13, 100288, 10.1016/j.bonr.2020.100288

Orimo, 2012, Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary, Arch Osteoporos, 7, 3, 10.1007/s11657-012-0109-9

Lewiecki, 2016, Best practices for dual-energy X-ray absorptiometry measurement and reporting: international society for clinical densitometry guidance, J Clin Densitom, 19, 127, 10.1016/j.jocd.2016.03.003

Ebina, 2018, Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naive rheumatoid arthritis, Osteoporos Int, 29, 1627, 10.1007/s00198-018-4492-y

Nenonen, 2005, 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover, J Bone Miner Res, 20, 1804, 10.1359/JBMR.050403

Kanda, 2013, Investigation of the freely available easy-to-use software EZR for medical statistics, Bone Marrow Transplant, 48, 452, 10.1038/bmt.2012.244

McClung, 2018, Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, Parallel Group Study, J Bone Miner Res, 33, 1397, 10.1002/jbmr.3452

Gasser, 2000, PTH and interactions with bisphosphonates, J Musculoskelet Neuronal Interact, 1, 53

Lindsay, 2006, A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide, J Bone Miner Res, 21, 366, 10.1359/JBMR.051109

Dempster, 2018, Remodeling- and modeling-based bone formation with teriparatide versus denosumab: a longitudinal analysis from baseline to 3 months in the AVA study, J Bone Miner Res, 33, 298, 10.1002/jbmr.3309

Lewiecki, 2019, One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study, J Bone Miner Res, 34, 419, 10.1002/jbmr.3622